Program

In-person AND virtual! – We are pioneering a new conference format that will connect in-person and virtual audiences to create a unique experience. Matching the innovation that comes through our members’ work, ISPOR is pushing the boundaries of innovation to design an event that works in today’s quickly changing environment. 

In-person registration included the full virtual experience, and virtual-only attendees will be able to tune into live in-person sessions and/or watch captured in-person sessions on-demand in addition to having a variety of virtual-only sessions to attend.

Evaluation of Utilization Patterns of Cough Medications in Ambulatory Care Settings in the United States: 2003-2018

Speaker(s)

Yang S1, Hincapie-Castillo JM2, Ke X3, Schelfhout J3, Ding H4, Sher M5, Wilson DL6, Lo-Ciganic WH6
1University of Florida, Ocala, FL, USA, 2University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 3Merck & Co., Inc., North Wales, PA, USA, 4Merck & Co., Inc., Chalfont, PA, USA, 5Center for Cough, Largo, FL, USA, 6University of Florida, Gainesville, FL, USA

Presentation Documents

OBJECTIVE: Cough is the most common patient-reported symptom. Little is known whether cough medication (CM) utilization patterns have changed over time or been influenced by the US opioid crisis. We examined trends in CM use among adult patient visits in US ambulatory care settings.

METHODS: Repeated cross-sectional analyses were conducted to examine CM use for office-based visits and emergency department (ED) visits using 2003-2018 National Ambulatory Medical Care Survey and 2003-2018 National Hospital Ambulatory Medical Care Survey data, respectively. Adult (≥18 years) visits with a cough-related diagnosis or reason-for-visit were included. Visits with any malignant cancer or benign respiratory tumor diagnoses were excluded. To obtain reliable estimates, we aggregated annual data into 5 consecutive time periods. Among cough-related visits, we used multivariable logistic regression to examine the trends in the use of opioid-containing antitussives, benzonatate, dextromethorphan-containing medications, and gabapentinoids, separately.

RESULTS: There were 819.9 million and 155.5 million cough-related visits in the office-based and ED settings from 2003 to 2018. Opioid-containing antitussive use decreased over time in office-based visits (8.8% in 2003-2005 to 6.4% in 2015-2018, Ptrend=0.03); while their use remained stable in ED visits (6.3% to 5.9%, Ptrend=0.99). In both settings, hydrocodone-containing antitussive use declined over 50%. From 2003-2005 to 2015-2018, benzonatate use more than tripled in both settings (office-based: 1.6% to 4.8%; ED: 1.5% to 8.0%; both Ptrend<0.001). Dextromethorphan-containing medication use increased in ED visits (1.8% to 2.6%, Ptrend=0.003), whereas their use stayed unchanged in office-based visits (3.8% to 2.7%; Ptrend=0.60). Gabapentinoid use doubled in office-based visits (1.1% in 2006-2008 to 2.4% in 2015-2018, Ptrend<0.001) but was negligible in ED visits.

CONCLUSIONS: In US office-based and ED ambulatory care settings, hydrocodone-containing antitussive use substantially declined from 2003 to 2018, while benzonatate use more than tripled, and dextromethorphan antitussive and gabapentinoid use remained low (<3%).

Code

HSD50

Disease

No Additional Disease & Conditions/Specialized Treatment Areas